EIF4EBP1 and lung carcinoma: Database from DepMAP also revealed that FGFR1-4EBP1-amplified cells were more sensitive to the FGFR1 inhibitor ponatinib compared to FGFR1-4EBP1-non-amplified cells in both breast and lung cancer cell lines (Figure 2E,F).